References
- Corey C, Wang B, Johnson SE, Apelberg B, Husten C, King BA, et al. Centers for Disease Control and Prevention. Notes from the field: electronic cigarette use among middle and high school students: United States, 2011-2012. MMWR 2013; 62:729–730.
- Dockrell M, Morrison R, Bauld L, McNeill A. E-cigarettes: prevalence and attitudes in Great Britain. Nicotine Tob Res 2013; 15:1737–1744.
- Vakkalanka JP, Hardison L Holstege C. Epidemiological Trends in Electronic Cigarette Exposures Reported to U.S. Poison Centers. Clin Toxicol 2014; 52:542–548.
- Cameron JM, Howell, DN, White JR, Andrenyak DM, Layton ME, Roll JM. Variable and potentially fatal amounts of nicotine in e-cigarette nicotine solutions. Tob Control 2014; 23:77–78.
- Schroeder MJ, Hoffman AC. Electronic cigarettes and nicotine clinical pharmacology. Tob Control 2014; 23:ii30–ii35.
- West R. Nicotine: a dependence-producing substance. Prog Clin Biol Res 1988; 261:237–259.
- Salokangas RK, Vlikman H, Ilonen T, Taiminen T, Bergman J, Haaparanta M, et al. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry 2000; 157:632–634.
- Trauth JA, Seidler FJ, Ali SF, Slotkin TA. Adolescent nicotine exposure produces immediate and long-term changes in CNS noradrenergic and dopaminergic function. Brain Res 2001; 892:269–280.
- Dutra LM, Glantz SA. Electronic cigarettes and conventional cigarette use among US Adolescents. A cross-sectional study. JAMA Pediatr 2014; published online March 6, 2014.
- Kim AE, Arnold KY, Makarenko O. E-cigarette advertising expenditures in the U.S., 2011-2012. Am J Prev Med 2014; 46:409–412.